These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28286803)

  • 1. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X; Pastan I; Bigner DD; Chandramohan V
    Receptors Clin Investig; 2016; 3(4):. PubMed ID: 28286803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V; Bao X; Keir ST; Pegram CN; Szafranski SE; Piao H; Wikstrand CJ; McLendon RE; Kuan CT; Pastan IH; Bigner DD
    Clin Cancer Res; 2013 Sep; 19(17):4717-27. PubMed ID: 23857604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V; Pegram CN; Piao H; Szafranski SE; Kuan CT; Pastan IH; Bigner DD
    Appl Microbiol Biotechnol; 2017 Apr; 101(7):2747-2766. PubMed ID: 28013405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.
    Bao X; Chandramohan V; Reynolds RP; Norton JN; Wetsel WC; Rodriguiz RM; Aryal DK; McLendon RE; Levin ED; Petry NA; Zalutsky MR; Burnett BK; Kuan CT; Pastan IH; Bigner DD
    Invest New Drugs; 2016 Apr; 34(2):149-58. PubMed ID: 26728879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V; Bao X; Yu X; Parker S; McDowall C; Yu YR; Healy P; Desjardins A; Gunn MD; Gromeier M; Nair SK; Pastan IH; Bigner DD
    J Immunother Cancer; 2019 May; 7(1):142. PubMed ID: 31142380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR; Boskovitz A; Kuan CT; Pegram CN; Ayriss J; Wikstrand CJ; Buckley AF; Lipp ES; Herndon JE; McLendon RE; Bigner DD
    Nucl Med Biol; 2012 Jan; 39(1):23-34. PubMed ID: 21958852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.
    Chandramohan V; Bigner DD
    Oncoimmunology; 2013 Dec; 2(12):e26852. PubMed ID: 24498557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
    Parker S; McDowall C; Sanchez-Perez L; Osorio C; Duncker PC; Briley A; Swartz AM; Herndon JE; Yu YA; McLendon RE; Tedder TF; Desjardins A; Ashley DM; Gunn MD; Enterline DS; Knorr DA; Pastan IH; Nair SK; Bigner DD; Chandramohan V
    Sci Transl Med; 2023 Feb; 15(682):eabn5649. PubMed ID: 36753564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
    Chandramohan V; Bao X; Kato Kaneko M; Kato Y; Keir ST; Szafranski SE; Kuan CT; Pastan IH; Bigner DD
    Int J Cancer; 2013 May; 132(10):2339-48. PubMed ID: 23115013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.